Retrospective Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6252-6263
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6252
Table 1 Characteristics and outcomes of the patients
All
Viral shedding (d)
P value
< 14
≥ 14
Total14553 (37%)92 (63%)
DemographicsAge, yr46.1 (42.6-49.9)39.6 (34.2-45.9)50.3 (46.1-54.9)0.004
Sex, male, n (%)79 (54.5%)25 (47.2%)54 (58.7%)0.18
BMI (kg/m2)23.6 (22.9-24.2)22.9 (21.9-24.1)23.9 (23.2-24.7)0.131
History of Hubei contact129 (89.0%)50 (94.3%)79 (85.9%)0.117
Smoking3 (2.1%)03 (3.3%)0.184
Symptom to admission (d)4.6 (4.1-5.1)4.4 (3.6-5.3)4.7 (4.1-5.3)0.553
Symptom to ICU (d)12.0 (10.8-13.4)10.5 (8.7-12.7)12.4 (10.9-14.2)0.236
ComorbiditiesHypertension26 (17.9%)5 (9.4%)21 (22.8%)0.043
Diabetes11 (7.6%)4 (7.6%)7 (7.6%)0.989
Heart disease18 (12.4%)3 (5.7%)15 (16.3%)0.061
COPD4 (2.8%)1 (1.9%)3 (3.3%)0.627
Laboratory findings on admissionTemperature (°C)37.4 (37.3-37.5)37.3 (37.0-37.5)37.5 (37.3-37.6)0.256
WBC (× 109/L)4.84 (4.58-5.12)4.89 (4.46-5.36)4.82 (4.49-5.16)0.784
PLT (× 1012/L)175.51 (166.47-185.05)201.84 (185.82-219.25)161.75 (151.91-172.23)< 0.001
LYMPH (× 109/L)1.20 (1.10-1.29)1.21 (1.06-1.37)1.19 (1.07-1.31)0.839
IL-6 (ug/L)18.24 (14.93-22.29)12.55 (8.58-18.36)21.72 (17.34-27.20)0.012
CR (mg/L)67.47 (64.12-71.00)62.03 (57.87-66.50)70.87 (66.21-75.86)0.013
Viral load in respiratory tract [log (copies)]3.69 (3.06-5.07)3.36 (2.49-4.83)4.22 (3.10-5.12)0.192
PAO2/FIO20.897
< 1001 (0.7%)01 (1.1%)
≥ 100, < 2008 (5.9%)3 (6.4%)5 (5.7%)
≥ 200, < 30019 (14.1%)7 (14.9%)12 (13.6%)
≥ 300107 (79.3%)37 (78.7%)70 (79.6%)
Severity scoreAPACHEII4.2 (3.7-4.7)3.4 (2.8-4.1)4.8 (4.2-5.5)0.003
SOFA1.7 (1.5-1.9)1.4 (1.2-1.7)1.9 (1.6-2.2)0.027
GCS14.8 (14.5-15.2)15.0 (15.0-15.0)14.7 (14.2-15.3)0.45
SymptomsFever123 (84.8%)41 (77.4%)82 (89.1%)0.057
Sore muscles32 (22.1%)13 (24.5%)19 (20.7%)0.588
Cough84 (57.9%)31 (58.5%)53 (57.6%)0.917
ARV in the first 3 d0.008
None16 (11.0%) 10 (18.9%)
Kaletra40 (27.6%)8 (15.1%)32 (34.8%)
Kaletra & Other ARV40 (27.6%)19 (35.9%)21 (22.8%)
Other ARV but Kaletra49 (33.8%)16 (30.2%)33 (35.9%)
ARV in the first 3 d0.014
016 (11.0%)10 (18.9%)6 (6.5%)
184 (57.9%)22 (41.5%)62 (67.4%)
238 (26.2%)18 (34.0%)20 (21.7%)
37 (4.8%)3 (5.7%)4 (4.4%)
Globulin61 (42.1%)12 (22.6%)49 (53.3%)< 0.001
Steroid57 (39.3%)12 (22.6%)45 (48.9%)0.002
Thymosin alpha-159 (40.7%)13 (24.5%)46 (50.0%)0.003
Antibiotics50 (34.5%)15 (28.3%)35 (38.0%)0.235
Other treatments11 (7.6%)011 (12.0%)0.009
HFO18 (12.4%)7 (13.2%)11 (12.0%)0.826
MV16 (11.0%)1 (1.9%)15 (16.3%)0.008
NMV46 (31.7%)11 (20.8%)35 (38.0%)0.031
CRRT4 (2.8%)0 4 (4.4%)0.124
OutcomeNegative108 (74.5%)53 (100%)55 (59.8%)< 0.001
Viral shedding (d)17.3 (15.8-18.9)12.1 (11.0-13.3)24.4 (22.6-26.3)< 0.001
Length of ICU stay (d)13.6 (9.4-19.8)7.0 (3.7-13.1)16.3 (10.7-24.9)0.067
Length of hospital stay (d)25 (23-28)21 (18-24)28 (25-32)0.002
Death3 (2.1%)03 (3.3%)0.184
Discharge57 (39.3%)29 (54.7%)28 (30.4%)0.004
Table 2 Univariate and multivariate regression analyses of the risk factors for viral shedding
VariablesUnivariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
Sex, male1.1 (0.7, 1.6)0.7570.8 (0.5, 1.3)0.422
Age (yr)
< 60Reference
≥ 600.5 (0.4, 0.8)0.0020.6 (0.4, 1.0)0.030
Diabetes0.9 (0.5, 1.8)0.8701.4 (0.7, 2.7)0.370
IVIG0.5 (0.3, 0.7)< 0.0010.6 (0.3, 1.2)0.182
Antibiotics0.5 (0.4, 0.8)0.0020.7 (0.4, 1.3)0.273
Steroids0.5 (0.3, 0.7)<0.0010.8 (0.4, 1.7)0.588
PAO2/FIO2
< 300Reference
≥ 3001.3 (0.8, 2.2)0.2471.0 (0.5, 1.7)0.898
Chloroquine26.8 (3.0, 239.3)0.00319.0 (1.9, 186.2)0.012
NLR1.0 (0.9, 1.0)0.3861.0 (1.0, 1.1)0.632
Table 3 Impact of severe acute respiratory syndrome coronavirus 2 viral shedding on outcomes
Non-adjusted
Model I
Model II

HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
ICU duration0.52 (0.90-0.96)0.020.49 (0.42-0.94)0.030.48 (-0.01-0.97)0.05
Hospital stay0.15 (-0.01,0.32)0.070.11 (-0.05-0.26)0.180.11 (-0.05-0.26)0.18
In-hospital mortality1.07 (0.98, 1.17)0.150.06 (-0.04-0.16)0.230.06 (-0.04-0.16)0.23